Brand-name antidepressants outperform their generic counterparts in preventing hospitalization for depression: The real-world evidence from Taiwan

Chih Wei Hsu, Sheng Yu Lee, Yao Hsu Yang, Liang Jen Wang*

*Corresponding author for this work

Research output: Contribution to journalJournal Article peer-review

6 Scopus citations

Abstract

Background: Generic antidepressants are approved on the market based on evidence of bioequivalence to their brand-name versions. We aimed to assess whether generic antidepressants exert equal effectiveness as their brand-name counterparts for treating patients with depressive disorders. Methods: In a nationwide, population-based cohort in Taiwan from 1997 through 2013, patients with a diagnosis of a depressive disorder aged between 18 and 65 years who were new users of antidepressant drugs were classified into either the brand-name group or the generic group. All patients were followed up until medication discontinuation or the end of the study period. We assessed the risk for hospitalization as a primary outcome and augmentation therapy, daily dose, medication discontinuation, or switching to another antidepressant as secondary outcomes. Results: A total of 277 651 brand-name users (35.8% male; mean age: 41.2 years) and 270 583 generic users (35.8% male; mean age: 41.0 years) were divided into 10 different antidepressant groups (fluoxetine, sertraline, paroxetine, escitalopram, citalopram, venlafaxine, mirtazapine, moclobemide, imipramine, and bupropion). We found that patients treated with the generic form of sertraline, paroxetine, escitalopram, venlafaxine, mirtazapine, and bupropion demonstrated significantly higher risks of psychiatric hospitalization (adjusted hazard ratios ranged from 1.20-2.34), compared to their brand-name counterparts. The differences between brand-name antidepressants and their generic counterparts in secondary outcomes varied across different drugs. Conclusions: Compared to most generic antidepressants, brand-name drugs exhibited more protective effects on psychiatric hospitalization for depressive patients. These findings could serve as an important reference for clinicians when encountering patients with depressive disorder.

Original languageEnglish
Pages (from-to)653-661
Number of pages9
JournalInternational Journal of Neuropsychopharmacology
Volume23
Issue number10
DOIs
StatePublished - 01 10 2021

Bibliographical note

Publisher Copyright:
© 2020 The Author(s).

Keywords

  • Antidepressant
  • Effectiveness
  • Formulation
  • Pharmacoepidemiology
  • Psychiatry

Fingerprint

Dive into the research topics of 'Brand-name antidepressants outperform their generic counterparts in preventing hospitalization for depression: The real-world evidence from Taiwan'. Together they form a unique fingerprint.

Cite this